These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30449208)

  • 1. Bone protection for early menopausal women in China: standard or half-dose estrogen with progestin? A one-year prospective randomized trail.
    Zhu SY; Deng Y; Wang YF; Xue W; Ma X; Sun A
    Gynecol Endocrinol; 2019 Feb; 35(2):165-169. PubMed ID: 30449208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmenopausal femur bone loss: effects of a low dose hormone replacement therapy.
    Gambacciani M; Ciaponi M; Cappagli B; Monteleone P; Benussi C; Bevilacqua G; Genazzani AR
    Maturitas; 2003 Jul; 45(3):175-83. PubMed ID: 12818462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of low-dose or standard-dose conjugated equine estrogen combined with different progesterone on bone density in menopause syndrome women].
    Zuo HL; Deng Y; Wang YF; Gao LL; Xue W; Zhu SY; Ma X; Sun AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Apr; 53(4):243-247. PubMed ID: 29747269
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of Menopausal Hormone Therapy on Bone Mineral Density in Chinese Women: A 2-Year, Prospective, Open-Label, Randomized-Controlled Trial.
    Zuo H; Sun A; Gao L; Xue W; Deng Y; Wang Y; Zhu S; Ma X; Xin H
    Med Sci Monit; 2019 Jan; 25():819-826. PubMed ID: 30690446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Half-dose and Standard-dose Conjugated Equine Estrogens Combined with Natural Progesterone or Dydrogesterone on Components of Metabolic Syndrome in Healthy Postmenopausal Women: A Randomized Controlled Trial.
    Xue W; Deng Y; Wang YF; Sun AJ
    Chin Med J (Engl); 2016 Dec; 129(23):2773-2779. PubMed ID: 27900987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early postmenopausal bone loss is prevented by estrogen and partially by 1alpha-OH-vitamin D3: therapeutic effects of estrogen and/or 1alpha-OH-vitamin D3.
    Gorai I; Chaki O; Taguchi Y; Nakayama M; Osada H; Suzuki N; Katagiri N; Misu Y; Minaguchi H
    Calcif Tissue Int; 1999 Jul; 65(1):16-22. PubMed ID: 10369728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis].
    Wu Y; Liu J; Xing S; Xu R; Zhang Z; Wang Y
    Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):267-70. PubMed ID: 12133397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.
    Thiébaud D; Bigler JM; Renteria S; Pache T; Welti HJ; Landry M; Burckhardt P
    Climacteric; 1998 Sep; 1(3):202-10. PubMed ID: 11907945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of two different dosages of conjugated equine estrogen in continuous combined hormone replacement therapy with progestin.
    Xing S; Wu Y; Liu J; Xu R; Zhang Z; Wang Y
    Chin Med J (Engl); 2003 Apr; 116(4):584-7. PubMed ID: 12875727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.
    JAMA; 1996 Nov; 276(17):1389-96. PubMed ID: 8892713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study.
    Mizunuma H; Okano H; Soda M; Kagami I; Miyamoto S; Tokizawa T; Honjo S; Ibuki Y
    Maturitas; 1997 May; 27(1):69-76. PubMed ID: 9158080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects on bone of oral hormone replacement therapy initiated 2 years after ovariectomy in young adult monkeys.
    Jayo MJ; Register TC; Carlson CS
    Bone; 1998 Oct; 23(4):361-6. PubMed ID: 9763148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of postmenopausal bone loss by low and conventional doses of calcitriol or conjugated equine estrogen.
    Ongphiphadhanakul B; Piaseu N; Tung SS; Chailurkit L; Rajatanavin R
    Maturitas; 2000 Feb; 34(2):179-84. PubMed ID: 10714913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy.
    Fogelman I; Fordham JN; Fraser WD; Spector TD; Christiansen C; Morris SA; Fox J
    Calcif Tissue Int; 2008 Aug; 83(2):85-92. PubMed ID: 18626566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group.
    Bone HG; Greenspan SL; McKeever C; Bell N; Davidson M; Downs RW; Emkey R; Meunier PJ; Miller SS; Mulloy AL; Recker RR; Weiss SR; Heyden N; Musliner T; Suryawanshi S; Yates AJ; Lombardi A
    J Clin Endocrinol Metab; 2000 Feb; 85(2):720-6. PubMed ID: 10690882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT.
    Rosen HN; Parker RA; Greenspan SL; Iloputaife ID; Bookman L; Chapin D; Perlmutter I; Kessel B; Qvist P; Rosenblatt M
    Calcif Tissue Int; 2004 May; 74(5):415-23. PubMed ID: 14961215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women.
    Prestwood KM; Gunness M; Muchmore DB; Lu Y; Wong M; Raisz LG
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2197-202. PubMed ID: 10852452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
    Reid IR; Eastell R; Fogelman I; Adachi JD; Rosen A; Netelenbos C; Watts NB; Seeman E; Ciaccia AV; Draper MW
    Arch Intern Med; 2004 Apr; 164(8):871-9. PubMed ID: 15111373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.